At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 147 enrolled
Drug / intervention
adalimumab +1 morebiological
Likely dose
adalimumab 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Open-Label Continuation Study of the Long-term Safety and Efficacy of Adalimumab (D2E7) in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating adalimumab for Psoriasis. Completed, enrolled 147 participants across 64 sites.
Detailed Summary
To evaluate efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with psoriasis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesJapan
CollaboratorsAbbott Japan Co.,Ltd, Eisai Co., Ltd.
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
Primary CompletionSep 2007
First PostedMar 2008
Study CompletionApr 2010
TodayJul 2026
First PostedMar 31, 2008
Enrollment StartApr 1, 2006
Primary CompletionSep 1, 2007
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.3 years ago
Interventions
adalimumabbiological
Adalimumab 40 mg every other week, subcutaneous
adalimumabbiological
Adalimumab 80 mg every other week, subcutaneous